Authors
Wendy De Roock, Derek J Jonker, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Dongsheng Tu, Salvatore Siena, Simona Lamba, Sabrina Arena, Milo Frattini, Hubert Piessevaux, Eric Van Cutsem, Chris J O’Callaghan, Shirin Khambata-Ford, John R Zalcberg, John Simes, Christos S Karapetis, Alberto Bardelli, Sabine Tejpar
Publication date
2010/10/27
Journal
Jama
Volume
304
Issue
16
Pages
1812-1820
Publisher
American Medical Association
Description
Context
Patients with metastatic colorectal cancer who have KRAS codon 12– or KRAS codon 13–mutated tumors are presently excluded from treatment with the anti–epidermal growth factor receptor monoclonal antibody cetuximab.
Objective
To test the hypothesis that KRAS codon 13 mutations are associated with a better outcome after treatment with cetuximab than observed with other KRAS mutations.
Design, Setting, and Patients
We studied the association between KRAS mutation status (p.G13D vs other KRAS mutations) and response and survival in a pooled data set of 579 patients with chemotherapy-refractory colorectal cancer treated with cetuximab between 2001 and 2008. Patients were included in the CO.17, BOND, MABEL, EMR202600, EVEREST, BABEL, or SALVAGE clinical trials or received off-study treatment. Univariate and multivariate analyses, adjusting for possible prognostic factors and data …
Total citations
Scholar articles
W De Roock, DJ Jonker, F Di Nicolantonio… - Jama, 2010